Quantitative EEG Evidence of Functional Brain Recovery in Parkinson’s Disease Following Biophoton Therapy
Author(s):
James Z Liu1,2*, Mariola A Smotrys1,2, Seth D Robinson2, Hui X Yu2, Sherry X Liu2, Devin R Liu2 and Helen Y Gu1,2
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder with limited treatment options that address both motor and non-motor
symptoms. Biophoton therapy, a non-invasive modality emitting biologically coherent light, may offer a novel approach to restoring functional brain activity
in PD patients by promoting cellular repair and neurophysiological rebalancing.Methods: This study employed quantitative electroencephalography (qEEG) and event-related potential (ERP) biomarkers to assess the neurophysiological
effects of biophoton therapy in multiple PD patients over a 4-week period. Each patient received continuous exposure to four strong biophoton generators.
EEG metrics analyzed included posterior alpha peak frequency, theta/beta ratio, ERP latencies (P300, N2, P2, N4), reaction times, error rates, and brain
region Z-scores associated with memory, attention, and motor control.Results: Patients demonstrated measurable neurophysiological improvements after biophoton therapy compared to baseline and placebo periods. Key
findings included reductions in posterior alpha frequency (indicative of decreased CNS hyperarousal), enhanced attention and vigilance (lowered theta/beta
ratios), faster ERP latencies (e.g., P300 latency improved from 340 ms to 320 ms), and improved motor performance (reaction time decreased from 841 ms
to 582 ms). Z-score analysis revealed normalization across Brodmann Areas 1–10, reflecting restored memory, impulse control, and emotional regulation.
No significant improvements were observed during placebo conditions.Conclusion: Strong biophoton generators produced consistent and clinically meaningful neurophysiological enhancements in Parkinson’s disease patients
within a 4-week window. This therapy may represent a safe, non-pharmacologic, and scalable intervention capable of reversing functional markers of
neurodegeneration. These results warrant larger controlled studies to confirm efficacy and explore underlying mechanisms.
